October 24, 2017 – Dublin, Ireland and Cambridge, UK - Inflazome, Ltd., a biotech company developing small molecule drugs that stop inflammation driven by our innate immune system, today announced the appointment of three leading experts in regulatory affairs, product development and biology to its Management Team as part of its transition to a development organisation.

Dr. Joanna Tufnell, Head of Regulatory Affairs - Dr Tufnell has over 30 years of experience in Regulatory Affairs and has worked on hundreds of applications for drug approvals globally. Dr Tufnell’s experience covers drug development, from first in man to phase 4, submitting INDs, approval of CTAs and liaising with Regulatory agencies. Dr Tufnell has held senior positions as Global Regulatory Lead for therapeutic areas including vaccines, oncology and HIV. She also has extensive experience with US and EU paediatric submissions and Orphan Designations. She was previously Head of Regulatory for start-up and established companies and has also worked for the Medicines and Healthcare Products Regulatory Agency (MHRA).

Dr. Laura Trespidi, Head of Product Development – Dr Trespidi has over 25 years of experience in the pharmaceutical industry in both in early and late stage product development. She joins Inflazome from Mundipharma International where she was Head of Technical Regulatory Affairs. Before this at Shire she held diverse senior R&D roles working on multiple drug development programs from candidate selection to market launch. She has also worked with GSK, NicOx AAI Pharma Services Corp. and Dompé Pharmaceutical. Dr Trespidi has experience in specialty drug delivery systems and scale-up of complex dosage forms. She has also extensive expertise in the management of business involved in the provision of services to Biotech and Pharma companies. 

Dr. Reena Halai, Biology Program Manager – Dr Halai joins Inflazome from the Wellcome Trust Sanger Institute where she was Project Manager for the Human Pluripotent Stem Cell Initiative. Dr Halai completed her PhD in Molecular and Structural Biology and completed Postdoctoral Research at The University of Queensland. Prior to her PhD, Dr Halai spent time at GSK, and UCB.


Other members of the Inflazome Management Team include:

·       Dr. Matt Cooper, Co-founder & Chief Executive Officer

·       Prof. Luke O’Neill, Co-founder & Chief Scientific Officer

·       Dr. Angus MacLeod, Vice President, Preclinical R&D

·       Dr. David Miller, Head of Medicinal Chemistry

·       Dr. Jeremy Skillington, Vice President, Business Development

 

About Inflazome

Inflazome is leading the development of orally available drugs to address clinical unmet needs in inflammatory diseases by targeting the inflammasome, which is now recognised to drive many chronic inflammatory conditions.